The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.
 
Caio Max S. Rocha Lima
Speakers' Bureau - Celgene; Genentech/Roche; Merrimack
 
Patrick J. Roberts
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
Patents, Royalties, Other Intellectual Property - G1 Therapeutics
 
Victor M. Priego
No Relationships to Disclose
 
Stephen G. Divers
No Relationships to Disclose
 
Melanie B. Thomas
No Relationships to Disclose
 
Ralph V. Boccia
No Relationships to Disclose
 
Katie Stabler
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Elizabeth Andrews
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Rajesh K. Malik
Employment - G1 Therapeutics
Leadership - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Raid Aljumaily
No Relationships to Disclose
 
John Turner Hamm
Consulting or Advisory Role - Genentech/Roche; Meda Pharmaceuticals
Speakers' Bureau - Janssen
 
Vi Kien Chiu
No Relationships to Disclose
 
Donald A. Richards
Consulting or Advisory Role - Boehringer Ingelheim; Insys Therapeutics; IntegraGen; Lilly; Merrimack; Pharmacyclics
Speakers' Bureau - Celgene
 
Petros Nikolinakos
No Relationships to Disclose
 
Maen A. Hussein
No Relationships to Disclose
 
Steven Robert Schuster
No Relationships to Disclose
 
Robert John Hoyer
No Relationships to Disclose
 
Geoffrey Shapiro
Consulting or Advisory Role - G1 Therapeutics; Lilly; Pfizer; Vertex
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
Konstantin H. Dragnev
No Relationships to Disclose
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Eisai; G1 Therapeutics; Genentech/Roche; Lilly; Novartis; Sandoz; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)